Skip to main content
An official website of the United States government
Email

Genitourinary Cancers Steering Committee

The Genitourinary Steering Committee (GUSC) was established in 2008. At monthly meetings, the GUSC addresses the design, prioritization, and evaluation of concepts for phase 2 and phase 3 clinical trials in genitourinary cancers. View the GUSC member roster as of May 30, 2024.

Strategic Priorities

  • GUSC Strategic Priorities were formulated with the goal that the majority of submitted concepts would align with these established priorities. They address areas of unmet clinical need, important unanswered clinical questions, and potential new approaches to disease treatment.

Task Forces

  • Task forces were established to discuss concepts and provide advisory input into concepts in each of the disease subtypes (View the GUSC Task Force member rosters as of May 30, 2024):
    • prostate
    • bladder
    • renal

Clinical Trial Planning Meetings (CTPMs)

CTPMs are held periodically and focus on specific clinical trial related topics. The following are important GUSC CTPMs:

  • Combination Therapies for High-Risk Non-Muscle Invasive Bladder Cancer
    In December 2022, the Bladder Task Force held a CTPM that focused on defining the next generation of clinical trials with combination therapies to improve bladder preservation rates and survival outcomes for patients with high-risk, including BCG-unresponsive, non-muscle invasive bladder cancer. Read the executive summary and publication on advancing biomarker studies in non-muscle invasive bladder cancer in Bladder Cancer 
  • Small Renal Masses and Early Stage Renal Cell Carcinoma
    In January 2020, the Renal Task Force held a CTPM that focused on improving the management of small renal masses and early-stage cell carcinoma cancer. Read the executive summary.
  • Novel Therapeutics for Non-Muscle Invasive Bladder Cancer
    In March 2015, the Bladder Task Force held a CTPM that focused on how to design clinical trials for non-muscle invasive bladder cancer using immunotherapy agents and targeted agents. Read the executive summary.
  • Advanced Renal Cell Cancer
    In February 2013, the Renal Task Force held a CTPM to review data on the use of molecular targeted therapy in renal cell carcinoma and frame the highest priority clinical and translational research questions. Read the executive summary.

Contact

For more information, contact NCI CCCT Program Director, Abdul Tawab Amiri, Ph.D., at atawab@mail.nih.gov.

Email